Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.59 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.55 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540566 | 1.00 | CD274 (0.59) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL20540450 | 0.93 | CD274 (0.67) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23949355 | 0.93 | CD274 (0.67) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL24613262 | 0.87 | CD274 (0.60) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL24613296 | 0.86 | CD274 (0.52) | CD274PDCD1 | |
| SCHEMBL23949536 | 0.81 | CD274 (0.68) | CD274PDCD1 | |
| SCHEMBL20539142 | 0.81 | CD274 (0.68) | CD274PDCD1 | |
| SCHEMBL20539444 | 0.81 | CD274 (0.54) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL20539448 | 0.81 | CD274 (0.54) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL23948919 | 0.80 | CD274 (0.60) | CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| CN-110799509-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2020-02-14 | — | — | CN | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
| US-20160083385-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885PDCD1LG2 3/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | CD274 1/4885PDCD1 3/4885PDCD1LG2 2/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885PDCD1LG2 3/4885 |
| US-20160083385-A1 | PYRAZINOISOQUINOLINE COMPOUNDS | H1-5, MTX2, H1-4 | CD274 3843/4885PDCD1 3652/4885PDCD1LG2 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.